As­traZeneca, Dai­ichi Sankyo un­cork new TNBC da­ta for 2nd part­nered ADC — and it's adding more heat un­der Gilead­'s Trodelvy

Af­ter the ap­proval of their part­nered an­ti-HER2 an­ti­body-drug con­ju­gate ear­li­er this year, As­traZeneca and Dai­ichi Sankyo are rid­ing high on the promise of their bloom­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER